tasks was compared between before and after escitalopram administration. Methods: The subjects were 10 depressive outpatients (40.2 ± 7.6 years old) attending Kurume University Hospital. HAM-D was used to evaluate symptoms. Oxy-Hb value during the tasks were measured at bilateral recording points (22 on each side) using a multi-channel NIRS system. The subjects were instructed to phonate "a-i-u-e-o" for 12 seconds as a resting condition, and performed a verbal production task (VPT) or shiritori task (saying a word starting with the last syllable). The shiritori task involved two task patterns, i.e., standard shiritori (VST) and living creatures shiritori (VLT). From the data obtained at each measurement point during the 20 trials, an averaged waveform was prepared, and peak values of waveform were calculated and analyzed. These tasks were performed before escitalopram administration (session 1(S1)) and 3.6 (S2) and 8.5 (S3) months after initiation of escitalopram administration. Results: When HAM-D was compared between before and after escitalopram administration, it significantly decreased in S2 and S3. No significant difference was noted in the number of words in the verbal task between before and after administration. Oxy-Hb value was significantly increased in the bilateral middle frontal regions in S3 of VLT compared with those before administration (S1). In the left frontal pole region, Oxy-Hb value significantly increased in the VST and VLT. A significant inverse correlation was observed between HAM-D and oxy-Hb value in the left middle frontal region. Discussion: Escitalopram was effective, and oxy-Hb value may serve as a useful psychophysiological index to evaluate drugs. et al., 2010). Desvenlafaxine is a newer SNRI used to treat depression, but there are no published studies on its benefits in chronic depression, or its influence on measure of HRV. The objectives of this pilot investigation were to investigate these issues. Methods: Twenty-three patients with persistent depressive disorder, who were enrolled in an open-label 8-week trial of monotherapy with desvenlafaxine, were included in this study. HRV was measured at baseline and post-treatment. Differences in HRV parameters were assessed pre-post treatment, as well as between those who responded to treatment (n=15) vs. non-responders (n=8).
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while SSRIs appear to have no influence on HRV (Kemp et al., 2010) . Desvenlafaxine is a newer SNRI used to treat depression, but there are no published studies on its benefits in chronic depression, or its influence on measure of HRV. The objectives of this pilot investigation were to investigate these issues. Methods: Twenty-three patients with persistent depressive disorder, who were enrolled in an open-label 8-week trial of monotherapy with desvenlafaxine, were included in this study. HRV was measured at baseline and post-treatment. Differences in HRV parameters were assessed pre-post treatment, as well as between those who responded to treatment (n=15) vs. non-responders (n=8).
Results: Across the sample, HRV measures of time-and frequency-domains significantly decreased over the course of treatment, including SDNN (p<.01), RMSSD (p=.05), RR triangular index (p=.03), as well as total Power (p<.01) and LF/HF Power (p=.03). Significant increases in frequency-domain measures such as HF power (p=.04) were also noted. Further, comparisons between responders and non-responders revealed significant differences in time-domain measures (TINN, p=.04), and overall estimates of HRV (RR triangular index) (p=.02) post-treatment.
Conclusions:
The results suggest that treatment response to desvenlafaxine is associated with normalization of sympathovagal balance (HRV). Limitations of this study include small sample size and absence of a control group. Additional investigations are warranted.
PS211
Fear conditioning induced by interpersonal conflicts in patients with dysthymic disorder Abstract Objective: The objective of this study was to detect specific psychophysiological response to interpersonal stimulus in dysthymic patients, using a newly-designed interpersonal conditioning experiment, and to elucidate the impact of their clinical characteristics and prescribed medications on the response. Method: Twenty female dysthymic subjects underwent fear conditioning and extinction experiments in response to two types of stimuli: an aversive sound, and pictures of an actors' face with recorded unpleasant verbal messages to cause interpersonal conflicts. Conditioned response was quantified by differential skin conductance response (SCR) between CS[+] and CS [-] . Regression analysis was performed to examine the effects of emotion regulation strategy measured by the Emotion Regulation Questionnaire (ERQ) and prescribed medications on the differential SCR. Result: Mean±SD age of the subjects was 29.2 ± 5.4. Twelve subjects received antidepressant drugs. The subjects successfully showed a fear conditioning in both sound and interpersonal conditions (CS[+]=0.55 and CS [-] =1.67, p=.11] ). However, they failed to extinguish the conditioned response during the last three extinction trials (CS[+]= 0.23, CS [-]=0.11 [t (19) =2.85, p=.01] ). In the interpersonal condition, the use of antidepressant drugs was negatively associated with the differential SCR during the late extinction phase (β=-.71, p=.02). Moreover, the ERQ expressive suppression score was positively associated with the differential SCR (β=.94, p=.01) and the ERQ cognitive reappraisal score was negatively associated with the differential SCR (β=-.88, p=.04) during the early extinction phase. Conclusions: Use of antidepressant drugs and emotional regulation strategy effectively enhanced the extinction of conditioned fear by interpersonal conflict in dysthymic patients, which suggests that antidepressant treatment and cognitive behavioral therapy may share, at least to some extent, the same target to treat in dysthymic patients.
